Patient Support Services Contact Us

The Orange Oakleaf Butterfly is similar to its surroundings with detail that sets it apart.

Created to be similar, With distinct value

CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection). Discover the comprehensive support and savings of CIMERLI Solutions and learn more about CIMERLI.


Immuno-oncology Begins Here

Developing immuno-oncology therapies for patients in need

The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.

We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.

About Coherus Immuno-oncology

Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines

Our approved products span multiple therapeutic areas including oncology, immunology and ophthalmology.

See our Products & Pipeline

Latest News

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)